aTyr Pharma (ATYR) reported second-quarter 2026 results and announced a corporate restructuring to prioritize its efzofitimod program in interstitial lung disease, including pulmonary sarcoidosis and SSc-ILD.
The company ended June 30, 2026, with $58.9 million in cash, cash equivalents, restricted cash and investments, and said its current cash position is expected to fund current operations into late 2028.
- Net loss attributable to aTyr Pharma was $10.3 million, or $0.11 per basic and diluted share, for the second quarter of 2026.
- Research and development expenses were $6.7 million, and general and administrative expenses were $4.1 million for the quarter.
- aTyr said it will reduce its workforce by approximately 60% and expects restructuring and other cost-saving measures to reduce annualized operating expenses by about $13 million beginning in the fourth quarter of 2026.
- The company submitted a protocol to the FDA in June 2026 for a planned Phase 3 study of efzofitimod in pulmonary sarcoidosis and expects feedback by the end of August 2026.
- Enrollment was completed in the Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD, with topline results expected in the first quarter of 2027.
- CFO Jill Broadfoot and General Counsel Nancy Denyes will step down as of Sept. 30, 2026, and Brandon Yaras will be appointed CFO on Oct. 1, 2026.
$ATYR Insider Trading Activity
$ATYR insiders have traded $ATYR stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ATYR stock by insiders over the last 6 months:
- PAUL SCHIMMEL purchased 100,000 shares for an estimated $49,630
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ATYR Hedge Fund Activity
We have seen 45 institutional investors add shares of $ATYR stock to their portfolio, and 45 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 4,616,572 shares (-71.6%) from their portfolio in Q2 2026, for an estimated $2,755,170
- UBS GROUP AG added 2,241,916 shares (+137.9%) to their portfolio in Q1 2026, for an estimated $1,748,694
- MILLENNIUM MANAGEMENT LLC added 1,641,246 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,280,171
- STATE STREET CORP removed 1,259,448 shares (-71.8%) from their portfolio in Q2 2026, for an estimated $751,638
- ROSALIND ADVISORS, INC. removed 1,039,080 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $810,482
- GSA CAPITAL PARTNERS LLP added 824,225 shares (+31.3%) to their portfolio in Q2 2026, for an estimated $491,897
- TWO SIGMA INVESTMENTS, LP added 690,122 shares (+151.9%) to their portfolio in Q1 2026, for an estimated $538,295
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
